4//SEC Filing
Atara Biotherapeutics, Inc. 4
Accession 0001209191-17-009533
$ATRACIK 0001604464operating
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 4:12 PM ET
Size
7.1 KB
Accession
0001209191-17-009533
Insider Transaction Report
Form 4
Turner Heather D
VP, General Counsel & Sec.
Transactions
- Sale
Common Stock
2017-02-09$15.70/sh−11,582$181,837→ 86,775 total - Sale
Common Stock
2017-02-09$16.16/sh−633$10,229→ 86,142 total
Footnotes (3)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.15 to $16.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.15 to $16.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001604464
Filing Metadata
- Form type
- 4
- Filed
- Feb 9, 7:00 PM ET
- Accepted
- Feb 10, 4:12 PM ET
- Size
- 7.1 KB